These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 34202213)

  • 1. Clinicopathological and Genomic Profiles of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma Identify Overlapping Signatures with a High Mutational Burden.
    Ak M; Kahraman A; Arnold FM; Turko P; Levesque MP; Zoche M; Ramelyte E; Dummer R
    Genes (Basel); 2021 Jun; 12(7):. PubMed ID: 34202213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profiles.
    Griewank KG; Wiesner T; Murali R; Pischler C; Müller H; Koelsche C; Möller I; Franklin C; Cosgarea I; Sucker A; Schadendorf D; Schaller J; Horn S; Brenn T; Mentzel T
    Mod Pathol; 2018 Mar; 31(3):418-428. PubMed ID: 29099504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas.
    Helbig D; Ihle MA; Pütz K; Tantcheva-Poor I; Mauch C; Büttner R; Quaas A
    Oncotarget; 2016 Apr; 7(16):21763-74. PubMed ID: 26943575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pleomorphic dermal sarcoma in a man with HIV: report with next-generation sequencing analysis and review of the atypical fibroxanthoma/pleomorphic dermal sarcoma spectrum.
    Chen SX; Eichenfield DZ; Orme C; Hinds B
    Dermatol Online J; 2019 Nov; 25(11):. PubMed ID: 32045146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A genomic survey of sarcomas on sun-exposed skin reveals distinctive candidate drivers and potentially targetable mutations.
    Miller TI; Zoumberos NA; Johnson B; Rhodes DR; Tomlins SA; Chan MP; Andea AA; Lucas DR; McHugh JB; Smith N; Harms KL; Brewer C; Saleh J; Patel RM; Harms PW
    Hum Pathol; 2020 Aug; 102():60-69. PubMed ID: 32540221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas.
    Griewank KG; Schilling B; Murali R; Bielefeld N; Schwamborn M; Sucker A; Zimmer L; Hillen U; Schaller J; Brenn T; Schadendorf D; Mentzel T
    Mod Pathol; 2014 Apr; 27(4):502-8. PubMed ID: 24030750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical expression of melanocytic and myofibroblastic markers and their molecular correlation in atypical fibroxanthomas and pleomorphic dermal sarcomas.
    Helbig D; Mauch C; Buettner R; Quaas A
    J Cutan Pathol; 2018 Dec; 45(12):880-885. PubMed ID: 30155964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pleomorphic Dermal Sarcoma.
    Saleh JS; Whittington CP; Bresler SC; Patel RM
    Surg Pathol Clin; 2024 Mar; 17(1):153-158. PubMed ID: 38278604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conception and Management of a Poorly Understood Spectrum of Dermatologic Neoplasms: Atypical Fibroxanthoma, Pleomorphic Dermal Sarcoma, and Undifferentiated Pleomorphic Sarcoma.
    Soleymani T; Tyler Hollmig S
    Curr Treat Options Oncol; 2017 Aug; 18(8):50. PubMed ID: 28762020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increase of atypical fibroxanthoma and pleomorphic dermal sarcoma: a retrospective analysis of four German skin cancer centers.
    Kuntz T; Siebdrath J; Hofmann SC; Baltaci M; Schaller J; Hellmich M; von Goltzheim LS; Assaf C; Oellig F; Michalowitz AL; Helbig D; Kreuter A
    J Dtsch Dermatol Ges; 2022 Dec; 20(12):1581-1588. PubMed ID: 36442137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clear cell variant of atypical fibroxanthoma and pleomorphic dermal sarcoma: Molecular characterization and review of the literature.
    Coelho-Lima J; Bruty J; Watkins J; Liu H; Price R; Stefanos N
    J Cutan Pathol; 2022 Dec; 49(12):1031-1034. PubMed ID: 35922373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S1-guideline atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS).
    Helbig D; Ziemer M; Dippel E; Erdmann M; Hillen U; Leiter U; Mentzel T; Osterhoff G; Ugurel S; Utikal J; von Bubnoff D; Weishaupt C; Grabbe S
    J Dtsch Dermatol Ges; 2022 Feb; 20(2):235-243. PubMed ID: 35099104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical fibroxanthoma and pleomorphic dermal sarcoma: Is superficial infiltration in subcutaneous tissue acceptable in AFX?
    van Midden D; Flucke UE; Amir AL; Bonenkamp JJ; Lubeek SFK; Blokx WAM
    Ann Diagn Pathol; 2022 Jun; 58():151915. PubMed ID: 35276548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic Mutation Profile of Atypical Fibroxanthoma and Cutaneous Undifferentiated Pleomorphic Sarcoma.
    Lim YH; Zaki TD; Levinsohn JL; Galan A; Choate KA; Hanlon AM
    Dermatol Surg; 2021 Feb; 47(2):290-292. PubMed ID: 32079866
    [No Abstract]   [Full Text] [Related]  

  • 15. Pleomorphic Dermal Sarcoma: A Clinical and Histopathologic Emulator of Atypical Fibroxanthoma, but Different Biologic Behavior.
    Carletti M; Nguyen DA; Malouf P; Ingersoll Z; Hosler GA; Weis SE
    HCA Healthc J Med; 2022; 3(5):299-304. PubMed ID: 37425251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical fibroxanthoma and pleomorphic dermal sarcoma: A reappraisal.
    Cesinaro AM; Gallo G; Tramontozzi S; Migaldi M
    J Cutan Pathol; 2021 Feb; 48(2):207-210. PubMed ID: 32583897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LN2, CD10, and Ezrin Do Not Distinguish Between Atypical Fibroxanthoma and Undifferentiated Pleomorphic Sarcoma or Predict Clinical Outcome.
    Hanlon A; Stasko T; Christiansen D; Cyrus N; Galan A
    Dermatol Surg; 2017 Mar; 43(3):431-436. PubMed ID: 28079637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical fibroxanthoma: new insights.
    Hussein MR
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):1075-88. PubMed ID: 24958232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pleomorphic dermal sarcoma: adverse histologic features predict aggressive behavior and allow distinction from atypical fibroxanthoma.
    Miller K; Goodlad JR; Brenn T
    Am J Surg Pathol; 2012 Sep; 36(9):1317-26. PubMed ID: 22510760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncological Safety and Recurrence in the Surgical Treatment of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma of the Scalp.
    Zeller J; Kiefer J; Braig D; Winninger O; Kraus D; Hagelstein S; Eisenhardt SU
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.